Massachusetts-based, Red Queen Therapeutics, a biotech company for clinical-stage raised $55 million led by Apple Tree Partners in a Series A.
Co-founder MD Ph.D. Loren Walensky, Biomedical researcher and Apple Tree Partners said that the initial funds will help them for development and expansion.
CEO Mark Mitchnick, Chief Scientific Officer Paul Da Silva Jardine in an interview said that Red Queen Therapeutics is at its initial stage and they have a proprietary stapled lipopeptide technology. This technology helps Red Queen to develop new specialized treatments for a broad range of viruses.
Moreover, Red Queen Therapeutics has an advanced biotech platform that rapidly develops antiviral therapies and delivers them quickly. The following are the advantages of new therapies over available antiviral vaccines:
- The new therapy does not depend on the host immune system and performs a fusion-inhibiting mechanism that acts directly on the virus.
- It inhibits viral fusion blocks all viral entry in the host body, and prevents host-cell infection.
- Single fusion-inhibits lipopeptide agents can fight against multiple virus and bacteria variants even within the same family.
Red Queen had signed a contract with BARDA for the preclinical development of pan-influenza therapeutic.
Also Read: Nob Hill Therapeutics Raised $3M Series A